Stakeholder Opinions: Ovarian Cancer - Approaching The Era Of Molecular Targeted Therapy Now Availab

Dallas, TX: ReportsandReports announce Japanese Stakeholder Opinions: Ovarian Cancer

- Approaching the era of molecular targeted therapy Market Research Report in its Store.

Browse complete Report at http://www.reportsandreports.com/market-reports/stakeholder-opinions-ovarian-cancer-approaching-the-era-of-mol/

Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovarian cancer. The high level of unmet need, coupled with the large size of the patient population, is driving extensive R&D interest in this indication. The anticipated incorporation of molecular targeted therapies into treatment is expected to improve patient outcomes in the future.

Scope

Ovarian cancer overview, including disease definition, epidemiology, discussion of unmet needs, and market potential

Current treatment options for ovarian cancer and ongoing controversies

Examination of the late-phase ovarian cancer pipeline, including drug profiles of late-stage agents

Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU

Highlights

Ovarian cancer is the leading cause of death from gynecological malignancies in the Western world. This is because the majority of epithelial ovarian cancer patients present with advanced disease at diagnosis, where treatment has a palliative rather than curative intent.

While first-line platinum-based chemotherapy can result in high response rates of over 70-80%, the majority of patients will advanced epithelial ovarian cancer will eventually relapse with incurable disease. As such, there is a need for novel first-line therapies to improve survival rates.

R&D interest in ovarian cancer is high. There are currently 85 drugs in the pipeline, which is dominated by molecular targeted therapies (42%) and cytotoxic therapies (33%). Competition for the approval of the first molecular targeted therapy in ovarian cancer is fierce.

Reasons to Purchase

Estimate the number of treatable patients and identify unmet needs for future drug development opportunities

Understand the current treatment of the disease, as well as opportunities and threats in the ovarian cancer market

Analyze the current ovarian cancer pipeline and the potential of late-stage drugs

Table Of contents

Overview 1

Catalyst 1

Summary 1

About Datamonitor healthcare 2

About the Oncology pharmaceutical analysis team 2

Executive Summary 3

Scope of the analysis 3

Datamonitor insight into the ovarian cancer market 3

Related reports 4

Upcoming reports 4

Table of Contents 5

Patient Potential 6

Key findings 6

Definition 6

Epithelial tumors 7

The vast majority of ovarian cancers are epithelial in origin 7

The majority of epithelial ovarian cancers are sporadic in nature 8

Germ cell tumors 8

Sex cord-stromal tumors 8

A successful screening test for ovarian cancer has not been developed 8

Ovarian cancer is a surgically staged malignancy 9

Epidemiology 12

The incidence of ovarian cancer in the seven major markets is forecast to reach nearly 63,000 cases by 2019 12

The highest ovarian cancer rates prevail in Northern European countries 14

Current treatment options 15

Most early-stage patients are treated with surgery and chemotherapy 15

Surgery has a central role in the management of advanced disease 16

First-line platinum-based chemotherapy is the standard of care for advanced disease 17

The use of intraperitoneal chemotherapy remains controversial 20

Maintenance therapy has not been shown to improve overall survival 21

The treatment of recurrent disease is rarely curative and depends on patients' platinum sensitivity 22

Platinum-based combination chemotherapy is recommended for platinum-sensitive recurrent disease 23

A number of single agents can be used in the treatment of platinum-resistant recurrent disease 25

Unmet need 25

More effective agents are required for the treatment of advanced disease 25

An effective screening test could significantly improve patient survival 26

R&D efforts should be directed towards molecular targeted therapies 26

Less invasive surgical approaches should be explored for early-stage patients 27

Market potential 28

Key findings 28

Current market overview 28

Opportunities and threats 29

Opportunities 29

Significant unmet need remains in the treatment of advanced disease 29

There is increased interest in the development of molecular targeted therapies 30

There is a large patient base in ovarian cancer, and a high commercial attractiveness 30

Threats 30

The development of an effective screening modality could decrease the patient base 30

Pipeline Analysis 31

Key findings 31

Ovarian cancer pipeline overview 31

Ovarian cancer late-phase pipeline 37

Avastin (bevacizumab; Genentech/Roche/Chugai) 37

Drug profile 37

Development overview 38

Product positioning 41

SWOT analysis 42

Karenitecin (cositecan; BNP-1350; BioNumerik) 43

Drug profile 43

Development overview 44

Product positioning 46

SWOT analysis 47

Opaxio (paclitaxel poliglumex; Cell Therapeutics/Novartis) 47

Drug profile 48

Development overview 48

Product positioning 49

SWOT analysis 50

Paclical (micellar paclitaxel formulation; Oasmia) 52

Drug profile 52

Development overview 52

Product positioning 53

SWOT analysis 54

Tarceva (erlotinib; Genentech/Roche/Chugai/OSI) 55

Drug profile 55

Development overview 55

Product positioning 58

SWOT analysis 59

Vargatef (intedanib; BIBF-1120; Boehringer Ingelheim) 60

Drug profile 60

Development overview 61

Product positioning 62

SWOT analysis 63

Votrient (pazopanib; GlaxoSmithKline) 63

Drug profile 63

Development overview 64

Product positioning 67

SWOT analysis 68

Farletuzumab (MORAb-003; Morphotek/Eisai) 69

Drug profile 69

Development overview 70

Product positioning 73

SWOT analysis 74

Abagovomab (Menarini/Cell Control Biomedical) 74

Drug profile 74

Development overview 75

Product positioning 77

SWOT analysis 77

Bibliography 79

Journals 79

Websites 84

Datamonitor reports 86

Appendix 87

Contributing experts 87

Report methodology 87

About Datamonitor 87

About Datamonitor Healthcare 87

About the Oncology analysis team 88

Disclaimer 90

List of Tables

Table 1: Staging of ovarian cancer using the International Federation of Gynecology and Obstetrics (FIGO) and American Joint Committee on Cancer (AJCC) classification 10

Table 2: Crude incidence rates of ovarian cancer per 100,000 population in the seven major pharmaceutical markets, 2002 12

Table 3: Forecast incidence of ovarian cancer in the seven major pharmaceutical markets, 2002-2019 12

Table 4: Top 5 countries with the highest crude incidence rates of ovarian cancer, 2002 14

Table 5: Survival results for randomized Phase III trials comparing cisplatin-paclitaxel with carboplatin-paclitaxel in advanced ovarian cancer 17

Table 6: Survival and selected toxicity results for randomized Phase III trial comparing docetaxel-carboplatin versus paclitaxel-carboplatin in ovarian cancer 18

Table 7: Randomized trials in platinum-sensitive ovarian cancer 23

Table 8: Selected clinical trial results for Yondelis presented at the American Society of Clinical Oncology (ASCO) meeting, June 2010 24

Table 9: Drugs approved by the US Food & Drug Administration (FDA) for the treatment of ovarian cancer 29

Table 10: Pipeline agents in Phase III development for ovarian cancer, 2010 31

Table 11: Pipeline agents in Phase II development for ovarian cancer, 2010 32

Table 12: Pipeline agents in Phase I development for ovarian cancer, 2010 34

Table 13: Avastin - drug profile, 2010 38

Table 14: Ongoing Phase III clinical trials for Avastin in ovarian cancer, 2010 39

Table 15: Selected Phase II trials of Avastin in ovarian cancer 40

Table 16: Karenitecin - drug profile, 2010 44

Table 17: Ongoing clinical trials for Karenitecin in ovarian cancer, 2010 45

Table 18: Phase II results for Karenitecin in the third-line treatment of recurrent or persistent platinum-resistant epithelial ovarian or primary peritoneal cancer 45

Table 19: Opaxio - drug profile, 2010 48

Table 20: Ongoing clinical trials for Opaxio in ovarian cancer, 2010 49

Table 21: Paclical - drug profile, 2010 52

Table 22: Ongoing clinical trials for Paclical in ovarian cancer, 2010 53

Table 23: Tarceva - drug profile, 2010 55

Table 24: Ongoing clinical trials for Tarceva in ovarian cancer, 2010 56

Table 25: Clinical trial results for Tarceva maintenance therapy in ovarian cancer 57

Table 26: Vargatef - drug profile, 2010 61

Table 27: Ongoing clinical trials for Vargatef in ovarian cancer, 2010 61

Table 28: Phase II results for Vargatef as maintenance therapy in advanced ovarian cancer 62

Table 29: Votrient - drug profile, 2010 63

Table 30: Ongoing clinical trials for Votrient in ovarian cancer, 2010 65

Table 31: Phase II results for Votrient maintenance therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer patients with a rising CA 125 level following first- or second-line therapy 66

Table 32: Farletuzumab - drug profile, 2010 69

Table 33: Ongoing clinical trials for farletuzumab in ovarian cancer, 2010 71

Table 34: Results of a Phase II study evaluating farletuzumab in platinum-sensitive ovarian cancer at first relapse, 2010 72

Table 35: Abagovomab - drug profile, 2010 75

Table 36: Ongoing clinical trials for abagovomab in ovarian cancer, 2010 75

Table 37: Phase I/II results for abagovomab as maintenance therapy in recurrent ovarian cancer 76

List of Figures

Figure 1: Cellular origin of the three main types of ovarian cancer 7

Figure 2: Stage distribution and corresponding 5-year survival rate for ovarian cancer in the US, 1999-2005 11

Figure 3: Forecast incidence and mortality of ovarian cancer in 2010 and 2019 across the seven major pharmaceutical markets 13

Figure 4: Forecast incidence of ovarian cancer in Brazil, Russia, India, and China, 2010 and 2019 15

Figure 5: Key unmet needs in ovarian cancer, 2010 25

Figure 6: Number of drugs in development for ovarian cancer by phase of development, 2010 35

Figure 7: Ovarian cancer pipeline by type of therapy, 2010 36

Figure 8: Ovarian cancer late-phase pipeline by type of therapy, 2010 37

Figure 9: Avastin - SWOT analysis in ovarian cancer, 2010 43

Figure 10: Karenitecin - SWOT analysis in ovarian cancer, 2010 47

Figure 11: Opaxio - SWOT analysis in ovarian cancer, 2010 51

Figure 12: Paclical - SWOT analysis in ovarian cancer, 2010 54

Figure 13: Tarceva - SWOT analysis in ovarian cancer, 2010 60

Figure 14: Vargatef - SWOT analysis in ovarian cancer, 2010 63

Figure 15: Phase II trial design for Votrient maintenance therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer patients with a rising CA 125 level following first- or second-line therapy 66

Figure 16: Votrient - SWOT analysis in ovarian cancer, 2010 69

Figure 17: Design of a Phase II study evaluating farletuzumab in platinum-sensitive ovarian cancer at first relapse 72

Figure 18: Farletuzumab - SWOT analysis in ovarian cancer, 2010 74

Figure 19: Abagovomab - SWOT analysis in ovarian cancer, 2010 78

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports

Browse all Newly Published Market Research Reports

Related Reports:

Stakeholder Opinions: Gastric Cancer - Targeted therapies compete for first-to-market status

Commercial Insight: Molecular Targeted Cancer Therapies

Cancer Ovarian Cancer Therapy Area Pipeline Report

About Us:

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Website: http://www.reportsandreports.com/

Blog: http://reportsnreports.wordpress.com/

Blog: http://reportsandreports.blogspot.com/

by: Ms.Sunita

POST COMMENT

Sciatica Treatment Sciatica Treatment - Work Outs That Will With Your Sciatica Heartburn Treatment for Occasional Heartburn Episodes Anxiety Attacks Treatment – Anxiety Attacks Help Anxiety Attacks Treatment – Social Anxiety Disorder Treatment Dry and Oily Skin Treatment Protect Your Delicate Skin By Using The Best Treatment For Undereye Dark Circles Best Treatment to Bad Breath using botox treatments to get immediate results for your battle against aging When Physicians Fail To Diagnose Prostate Cancer Until It Spreads Know Information About Signs Of Cancer Now We Have Laser Treatments for the Skin Know More About Signs Of Skin Cancer